Our Mission
CytoSen Therapeutics is an innovative team of medical and scientific professionals on a mission to advance natural killer (NK) cell therapeutics and to make it a real cure in the fight with cancer. Our mission is to make an effective, expedient, and accessible NK cell therapy for patients and providers at a wide range of points-of-care. CytoSen’s nanoparticle-based technology for NK cell production combined with the potential for multiple indications with wide accessibility allows the potential to treat thousands of cancer patients.
Technology
CytoSen is bringing innovation to NK cell therapy by generating large numbers of highly-active NK cells with its nanoparticle-based “expansion and activation” process. Born from the intersection of cellular immunotherapy and nanotechnology, CytoSen’s NK cell therapy harnesses the power of the immune system to treat cancer.
Broad Cancer Fighting Potential
Unlike many immuno-oncology therapies being investigated today, CytoSen’s unique, patented methods produce cellular immunotherapeutics that are scalable, robust, and accessible. Without a requirement for genetic modification or manipulation, CytoSen’s NK cell therapy have the potential to treat a broad range of cancers.
Broad Cancer Fighting Potential
Unlike many immuno-oncology therapies being investigated today, CytoSen’s unique, patented methods produce cellular immunotherapeutics that are scalable, robust, and accessible. Without a requirement for genetic modification or manipulation, CytoSen’s NK cell therapy have the potential to treat a broad range of cancers.
News
CytoSen Therapeutics Appoints Scientific Advisory Board
Orlando, Fla., October 23, 2017 – CytoSen Therapeutics announced today the appointment of five new members to the company’s scientific and medical advisory board. Drs. Michael Caligiuri, Zhijian “James” Chen, Todd Fehniger, Helen Heslop, and Jeffrey Miller will join...
read moreResearchers show feasibility of ex vivo expanded NK cell therapy for acute myeloid leukemia
Researchers from multiple institutions, including Drs. Stefan Ciurea and Dean Lee, published data last month showing the feasibility and safety for preventing relapse of acute myeloid leukemia (AML) by treating with ex vivo expanded NK cells in combination with...
read more